Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | MTTP | P55157 | 7/20 | 0.52 |
| ▸ | APOB | P04114 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606603 | 0.91 | CES1 (0.55) | SMOTRPV1KDRMTTPAPOB | |
| SCHEMBL6793033 | 0.90 | TRPV1 (0.52) | SMOTRPV1KDRMTTPAPOB | |
| SCHEMBL6794587 | 0.90 | SMO (0.55) | SMOKDRMTTPAPOBGAA | |
| SCHEMBL6492242 | 0.89 | GCGR (0.49) | SMOTRPV1KDRMTTPGRM4 | |
| SCHEMBL6799242 | 0.89 | CHRNB2 (0.59) | SMOKDRGAAGRM4 | |
| SCHEMBL6794304 | 0.88 | GRM4 (0.55) | KDRGRM4 | |
| SCHEMBL6788420 | 0.87 | MTTP (0.57) | TRPV1KDRMTTPAPOBGAA | |
| SCHEMBL6793810 | 0.87 | KDR (0.52) | KDRGRM4 | |
| SCHEMBL6793626 | 0.87 | NAMPT (0.56) | SMOTRPV1KDRMTTPAPOB | |
| SCHEMBL6799904 | 0.86 | MTTP (0.50) | SMOMTTPAPOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | claimed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SMO 2094/4885TRPV1 3714/4885KDR 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.